Emerging drugs for the treatment of bladder storage dysfunction
INTRODUCTION: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents.
AREAS COVERED: New b3-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase.
EXPERT OPINION: New potential alternatives to currently used drugs/drug principles are emerging, but further clinical testing is required before they can be evaluated as therapeutic alternatives. It seems that for the near future individualized treatment with approved drugs and their combinations will be the prevailing therapeutic approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 27(2022), 3 vom: 20. Sept., Seite 277-287 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andersson, Karl-Erik [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cannabinoids |
|---|
| Anmerkungen: |
Date Completed 08.11.2022 Date Revised 06.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2022.2113057 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344943798 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344943798 | ||
| 003 | DE-627 | ||
| 005 | 20231226023930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2022.2113057 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344943798 | ||
| 035 | |a (NLM)35975727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andersson, Karl-Erik |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging drugs for the treatment of bladder storage dysfunction |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2022 | ||
| 500 | |a Date Revised 06.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Current drug treatment of lower urinary tract disorders, for example, overactive bladder syndrome and lower urinary tract symptoms associated with benign prostatic hyperplasia, is moderately effective, has a low treatment persistence and some short- and long-term adverse events. Even if combination therapy with approved drugs may offer advantages in some patients, there is still a need for new agents | ||
| 520 | |a AREAS COVERED: New b3-adrenoceptor agonists, antimuscarinics, the naked Maxi-K channel gene, a novel 5HT/NA reuptake inhibitor and soluble guanylate cyclase activators are discussed. Focus is given to P2X3 receptor antagonists, small molecule blockers of TRP channels, the roles of cannabis on incontinence in patients with multiple sclerosis, and of drugs acting directly on CB1 and CB2 receptor or indirectly via endocannabinoids by inhibition of fatty acid aminohydrolase | ||
| 520 | |a EXPERT OPINION: New potential alternatives to currently used drugs/drug principles are emerging, but further clinical testing is required before they can be evaluated as therapeutic alternatives. It seems that for the near future individualized treatment with approved drugs and their combinations will be the prevailing therapeutic approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cannabinoids | |
| 650 | 4 | |a P2X3 receptor antagonists | |
| 650 | 4 | |a TRP channel blockers | |
| 650 | 4 | |a lower urinary tract symptoms | |
| 650 | 4 | |a overactive bladder | |
| 650 | 4 | |a sGC activators | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 27(2022), 3 vom: 20. Sept., Seite 277-287 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:3 |g day:20 |g month:09 |g pages:277-287 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2022.2113057 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 3 |b 20 |c 09 |h 277-287 | ||